A therapy, possibly called rocatinlimab, has shown activity in treating atopic dermatitis in patients who have been previously treated. However, there are conflicting reports about the status of the therapy's development, with some outlets indicating it has shown improvement in symptoms and others stating that trials have been discontinued due to safety issues. The therapy, which targets OX40, is associated with companies including Kyowa Kirin and Amgen, although the extent of their involvement is unclear.